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Introduction
Viral hepatitis remains a major, worldwide health issue. 
Recent reports from the World Health Organization [1, 2] 
estimate that 1.34 million deaths occur yearly by viral hep-
atitis B and C infections and its sequelae. Testing guide-
lines and a call to eradicate chronic viral hepatitis by 2030 
have been recently released by the WHO, underpinned by 
advances in diagnostics and the availability of effective 
treatment [3, 4]. Screening for HBV is cost-effective in 
migrant populations [10], but the linkage to care is a com-
mon challenge in these initiatives. Of all migrant popula-
tions in the European Union as a whole, individuals from 
Chinese descent make up the highest number of esti-
mated HBV infected patients, with HBV seroprevalences 
of 6.2%–8.7% [5, 7, 8].
Screening of this hard-to-diagnose population has 
often been performed by community outreach methods, 
wherein medical staff performs screening on-site, coop-
erating with Chinese communities [6, 9]. The Centres for 
Disease Control’s Hepatitis Testing and Linkage to Care 
(HepTLC) project showed that less than half of individu-
als who tested positive for HBsAg attended a first medical 
appointment [11]. Multiple barriers to care exist in several 
infectious diseases, including in hepatitis B infection care 
[12]. In sexually transmitted infections and HIV care, point-
of-care tests (POCT) have been shown to overcome most of 
these barriers to care, but their impact on linkage to care 
in viral hepatitis B remains undetermined [13]. Recently, 
rapid POCT has become available for HBsAg. The perfor-
mance characteristics of certain tests are excellent with 
sensitivities of 99.9% and specificities of 99.8% [14, 15].
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Background: This study compares venepuncture versus point-of-care (POC) HBsAg tests on screening 
cost and linkage to care in prospective outreach screenings in an Asian population in three major cities in 
Belgium between 10/2014 and 5/2018.
Methods: Two community outreach screening programs were organised between 10/2014 and 5/2018. 
The first screening program used venepuncture and serologic testing for HBsAg. In the second program, 
HBsAg was tested in finger stick blood POC tests. Positive results were confirmed during outpatient visits 
with serologic testing. Linkage to care was defined as having received specialist care follow-up with at 
least one abdominal ultrasound within three months of screening.
Results: For 575 participating individuals, 571 valid results were obtained, 456 with venepuncture, and 
115 using POC testing. Overall HBsAg seroprevalence was 6.8%. Linkage to care was higher when using 
POC testing compared to venepuncture (86% or n = 6/7 versus 34% or n = 11/32; p = 0.020). The 
POC screening program was economically more attractive with a total cost of € 1,461.8 or € 12.7 per 
person screened compared to € 24,819 or € 54.0 per person screened when using venepuncture testing. 
Results and an appointment for specialist care follow-up were given onsite with POC testing, while with 
venepuncture testing; results were sent within 20–45 days.
Conclusion: In an Asian migrant population in Belgium with an HBsAg seroprevalence of 6.8%, HBV screen-
ing based on POC tests resulted in lower costs per person screened (76.5% lower), and higher linkage to 
care (2.5 times).
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Methods
This study aims to compare screening costs and linkage to 
care for viral hepatitis B infection in a migrant population 
with high expected seroprevalences using POCT or stand-
ard venepunctures during outreach screening activities.
Between 10/2014 and 5/2018, community screening 
programs were organised with the cooperation of Chinese 
community leaders, Chinese organisations and the 
Antwerp City Council. This allowed us to screen the same 
Asian population through multiple angles: during com-
munity events in various locations (churches, temples, 
and a local public library in Antwerp and adjacent major 
Belgian cities), in Asian massage parlours in Antwerp, and 
through opportunistic testing during mandatory integra-
tion classes.
Patient and Public Involvement
Community leaders, volunteers, and screened persons 
of the Chinese community all participated before, dur-
ing, and after the various screening events. Preparatory 
meetings were organized to disseminate the rationale of 
the study and make arrangements for the logistics of the 
screening events. A pre-screening questionnaire, commu-
nication through written media, social media, and word-
to-mouth were used. During screening events, community 
members, translators, and Antwerp City Council social 
workers assisted in logistics and translation services. After 
screening events, community members also assisted in 
translation during telephone calls for results and to set up 
outpatient appointments.
Venepuncture testing for HBsAg was subsequently 
performed in the Antwerp University Hospital labo-
ratory (Elecsys HBsAg II, Roche Diagnostics GmbH, 
Mannheim, Germany). POC testing for HBsAg was done 
with Vikia HBsAg tests (Biomérieux SA, Marcy-l’Etoile, 
France), according to the package insert. Testing was 
performed pseudonymised (no personal details were 
provided but results were given to the screened person) 
to maximize screening uptake in this difficult-to-reach 
population. Serologic results were given on-site after 
an incubation time of 15 minutes for the Vikia test, as 
per the package insert. Upon receiving a positive result, 
patients were identified and an appointment for special-
ist care follow-up was immediately agreed upon. POC 
tested patients’ results were confirmed using the stand-
ard of care serologic testing (Elecsys HBsAg II, Roche 
Diagnostics GmbH, Mannheim, Germany) at their first 
outpatient visit.
Inclusion criteria were: being of Asian descent, first- or 
second-generation migrant and birth date before 1999, 
which is the year of starting universal HBV vaccination in 
Belgium. Excluded were individuals <18 years old at the 
screening event and third-generation migrants. Minimal 
clinical data were obtained after informed consent. Data 
obtained included: age, gender, nationality, place of birth, 
HBV infection status, HBV vaccination status, and previous 
or ongoing anti-viral treatment. Results were sent through 
the mail and positively screened persons were notified by 
phone and also invited for specialist care follow-up.
Additional reflex biochemical (ALT) and virological tests 
were performed on HBsAg positive samples (HBeAg and 
anti-HBe antibody: Liaison, DiaSorin, Saluggia, Italy; HBV 
DNA: in-house method).
Screening uptake was defined as participating with the 
screening programs when reached (in any of the described 
screening events) and providing a valid serological result. 
Linkage to care was defined as having received specialist 
care follow-up within three months with HBsAg, HBeAg, 
anti-HBe antibody, ALT, and HBV DNA test results, and 
at least one abdominal ultrasound. Analysis of linkage 
to care was finalised three months after the last screen-
ing activity by cross-checking positively screened persons 
and the presence of out-patient clinic patient files at the 
Antwerp University Hospital. Treatment and hepatocellu-
lar carcinoma (HCC) surveillance indications were based 
on international clinical practice guidelines [23, 24]. All 
costs associated with the screening activities (personnel, 
screening tests, other test materials, event-related costs 
such as fees for screening locations, and communication 
costs) are listed in the euro. Tests performed in the follow-
up were excluded, as they were not billed to the patients. 
Turn-around times, or the amount of time passed between 
venepuncture and posting of results in the venepuncture, 
were calculated in days.
Statistics
Before the study, a power analysis was performed to ascer-
tain a valid sample size for the seroprevalence of HBV. Pre-
vious studies of similar scope [5–7] report a prevalence 
of HBV infection of 8.5–8.7%. Considering estimates of 
the Chinese population in Belgium of approximately 
13,000–23,000 individuals [16] and extrapolation of 
6,239 East Asians in Antwerp city proper in 2014, a power 
analysis with a precision of 5% (confidence interval of 
95%) yielded a required sample size of n = 119.
To determine differences in sampling, the seropreva-
lence of HBsAg between the two screening programs 
was compared using the Chi-square test. To compare 
screened persons’ characteristics in terms of linkage to 
care,  students’ T-tests were used to compare continuous 
variables. Chi-square or, where applicable, Mid-P exact test 
was used to compare ordinal and categorical variables, 
including the association between screening programs 
and  linkage to care. Given the absence of estimates on dif-
ferences in linkage to care for both screening programs, 
no a priori power calculation thereof was performed.
Statistical tests were performed using SPSS version 
24.0 (IBM Corp. Released 2016. IBM SPSS Statistics for 
Windows, Version 24.0. Armonk, NY: IBM Corp.).
Results
Organisation of screening
Seven events were held between 10/2014 and 12/2015 
(Antwerp: n = 4; Brussels: n = 2 and Leuven n = 1). Both 
religious (two Christian fellowships/churches, a Buddhist 
temple) and non-religious focus groups (Hong Kongese 
and other Chinese societies) were involved. Subsequently, 
thirteen events were held between 12/2015 and 5/2018 
in Antwerp, in 23 massage parlours, five events in class-
rooms of the Atlas Integration and Citizenship Education 
organization, and one time at the Antwerp University 
 Hospital. Details are listed in Table 1.
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Epidemiology, Demographics
In total, 575 persons participated, and 571 individuals 
were serologically screened. Using venepuncture, 456 
persons had valid serologic results, and 115 persons were 
screened using POC testing. Overall, seroprevalence for 
HBsAg was 6.8% (39/571), with 32 and 7 individuals 
testing positive by venepuncture and POCT respectively. 
There was no statistically significant difference in HBsAg 
seroprevalence in both screening methods (7.0% vs 6.1%, 
p = 0.661). An overview is shown in Figure 1. One person 
who tested positive for HBsAg was a second-generation 
migrant. This person was born before 1999, before uni-
versal vaccination in Belgium and also before generalised 
HBsAg pregnancy testing in 1982.
Impact of point-of-care testing: comparison of 
linkage to care, cost
The average turnaround time was 32 days (20–45 days, 
Figure 2) for venepuncture samples. Results were imme-
diately available with POC testing. Eleven of the 32 HBsAg 
positives diagnosed using venepuncture (34%) were 
linked to specialist care, compared to six of the seven posi-
Table 1: Screening protocols and characteristics.
Screening Protocols and Characteristics Venepuncture Point-of-care test
Cooperating partners Chinese community 
– Key opinion leaders
City of Antwerp/Atlas Integration 
and  Citizenship Education/Church
Number of hospital staff 4–7 1
Number screening events 7 13
Number screening sites 5 27
Number of screened persons 460 115
Figure 1: Overview of linkage to care of community screening using venepuncture and point-of-care testing (POCT).
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tive patients diagnosed with POC testing (86%) (Figure 1; 
p = 0.020). As we collected demographic data in the total 
venepuncture cohort after informed consent and in those 
linked to care for POCT, we were able to analyse differ-
ences in demographics between patients linked to care 
in both programs, as well as those not-linked to care in 
the venepuncture program: Age, gender, country of origin 
and place of residence were not associated with linkage to 
care, or the absence thereof in the venepuncture program 
(Table 2). There was no difference in the proportion of 
patients who met HCC surveillance criteria or treatment 
indications. Nor was there a difference in ALT and HBV 
DNA elevation between linked and non-linked patients 
in the venepuncture program. Ten (25.6%; 10/39) and 
three (7.7%; 3/39) of identified HBV patients met criteria 
for HCC surveillance or treatment initiation respectively 
[23] but were lost to follow-up (Table 2). Two patients 
screened with venepuncture are currently being treated 
Figure 2: Turn-around time (time-to-result in days) for results of venepuncture screening.
Table 2: Characteristics of screened persons not linked to care/linked to care.
All (n = 39) Not linked to care1 (n = 22) Linked to care (n = 17) p Value
Demographics
Age (mean, years)2 46.5 46.8 45.1 0.12
Gender (female, %) 22 (56.4) 12 (54.5) 10 (58.8) 0.79
Country of origin (China, %) 38 (97.4) 22 (100) 16 (94.1) 0.25
Residence (Antwerp, %) 19 (48.7) 10 (45.5) 9 (52.9) 0.64
Type of screening (POCT,6 %) 7 (17.9) 1 (4.5) 6 (35.3) 0.02
Liver disease
HCC surveillance indication (yes, %)2 18 (50.0) 10 (47.6) 8 (44.4) 0.96
Treatment indication (yes, %)2 6 (16.7) 3 (13.6) 3 (16.7) 0.73
Significant liver fibrosis4 3 (13.6) – 3 (16.7) –
HBV clinical phase3
ALT > ULN (%)5 8 (22.2) 4 (19.0) 4 (26.7) 0.59
HBV DNA > 2,000 lU/mL (%) 13 (36.1) 7 (33.3) 6 (42.9) 0.57
HBV DNA > 20,000 IU/mL (%) 7 (19.4) 3 (14.3) 4 (28.6) 0.3
HBeAg (%) 2 (5.1) – 2 (11.8) –
1 Linked to care = specialist care follow-up with HBsAg, ALT and HBV DNA test results and at least 1 abdominal ultrasound.
2,3 Data available for 90% and 92% of patierns, respectively.
4 detected using shear wave elastography, 6 kPa or above [25].
5 Upper Limit of Normal ALT: 41 U/L for males, 31 U/L for females.
6 POCT: Point-of-care testing.
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with antiviral therapy according to their natural history 
and international treatment recommendations. For one 
patient screened with POC testing, antiviral treatment is 
being planned after a liver biopsy [21, 22]. None of the 
patients who were linked to care tested positive for anti-
Hepatitis C antibodies or anti-hepatitis Delta antibodies.
The costs associated with screening are shown in detail 
in Table 3.
Overall, the costs for screening were € 24,819 and 
€ 2,750 for venepuncture and POC testing respectively. 
Taking into account the number of persons screened, 
the screening cost per person is € 54.0 and € 11.4 for 
venepuncture and POC testing respectively (Figure 3). 
Screening uptake differed between the two screening 
methods. While screening uptake was 100% when screen-
ing with venepuncture, uptake was 88.8% when using 
POC testing. Taking this into account, per person screen-
ing cost of the POC testing is € 12.7. Total adjusted cost 
saving is €41.3 or 76.5%.
Discussion
This study provides empirical proof that POC screening 
tests for viral hepatitis B are associated with a higher 
linkage to care in an Asian migrant population, despite 
a lower overall cost and lower cost per person screened.
The WHO recently launched its ambition to eliminate 
viral hepatitis B and C infections as a public health prob-
lem by 2030 [3]. Although diagnostic tests with high-
performance characteristics [14, 15] and effective antiviral 
treatments are available, attaining the ambitious WHO 
goal will depend on identifying currently unknown car-
riers and linking them to specialist care. Linkage to care 
remains suboptimal, certainly in populations where viral 
hepatitis is highly endemic. In our data, a pressing sign of 
the importance of linkage to care is that 7.7% (n = 3/39) 
and 25.6% (n = 10/39) of the identified HBV patients who 
had treatment and HCC surveillance indications respec-
tively in the venepuncture program [22], were lost to 
 follow-up (Table 2).
Interestingly, a recent study by Sehr et al [19]. used 
Markov modelling to predict that POC testing may decrease 
long-term complications due to chronic HBV infection 
and improve linkage to care. Our data empirically support 
the wider implementation of POC testing due to its higher 
linkage to care of 86% of identified patients.
Only one-third of HBsAg positive individuals were 
linked to care using venepuncture-based testing, a result 
corroborated by numerous other studies [9, 11, 17, 18]. 
Multiple barriers towards screening and linkage to care 
in regards to viral hepatitis exist in the Chinese com-
munity. A recent qualitative study by Lee et al [12]. high-
lights determinants in knowledge, cultural beliefs, social 
stigma, awareness, and views towards Western health 
systems as major contributors as to why viral hepatitis is 
an “invisible disease in an invisible population”. Barriers 
to care have also been investigated in other populations 
and HCV, HIV, and testing of sexually transmissible dis-
eases [8, 13]. Linkage to care was enhanced by facilitating 
referral for HCV assessment and scheduling of specialist 
appointments for screened persons. Barriers described in 
HIV testing included transport costs and distance, stigma, 
and fear of disclosure–factors similar to those described in 
screening for viral hepatitis in Asian populations.
Finally, we observed an overall HBsAg seroprevalence of 
6.8% in the Asian, predominantly Chinese migrant com-
munity in three major cities in Belgium, which is in line 
with similar studies from the UK and the Netherlands 
[5–7].
Many potential issues and limitations must be addressed 
in our study.
Table 3: Overall costs of venepuncture and point-of-care testing (POCT) screening (in euros).
Venepuncture POC
Personnel Nursing staff 3634.0 0.0
Administrative assistant 1157.7 0.0
Language services 160.0 0.0
Study coordinator 1719.8 1013.5
Physicians 4366.8 0.0
TOTAL 11038.3 1013.5
Logistics Blood tubes, venepuncture materials 4737.2 46.2
Serological tests: HBsAg 7332.5 254.9
Event logistics (location rent, catering, etc) 500.0 0.0
Communication costs 1211.0 0.0
TOTAL 13780.7 301.1
OVERALL COST 24819.0 1314.6
Screening uptake 100% 88.8%
ADJUSTED COST 24819.0 1461.8
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First, it could be argued that the samples of both screen-
ing methods are not the same: venepuncture and POC 
tests were not randomised side by side at each screening 
site. However, the lack of statistical difference in seroprev-
alence of HBsAg between both protocols provides indirect 
evidence on the contrary. Also, when observing screened 
persons’ characteristics as a whole and comparing posi-
tively screened individuals based on their linkage to care 
(Table 2), all described characteristics showed no statisti-
cally significant difference across both groups except the 
screening method used (p = 0.020).
Second, while this study focused on the effect of POC 
testing on linkage to care, other factors besides the test 
modality differed between screening protocols. During 
venepuncture screening, persons were specifically moti-
vated by community leaders and through peers to get 
tested. This may explain the observed higher screening 
uptake. POC testing was mostly an opportunistic screen-
ing during classes/professional activities. As opportunis-
tic screening generally has a lower impact [23], the higher 
linkage to care during POC testing further underlines 
the importance of providing on-site results to motivate 
patients for clinical follow-up.
Finally, an a priori power analysis for linkage to care was 
not possible. Using observed data, however, the estimated 
power surpasses 80%. The high prevalence of HBV in this 
population and their well-known low rate of linkage to 
care allowed investigating the impact of POCT on link-
age to care. Such an impact would be harder to assess in 
Caucasians living in a low seroprevalence area and with 
generally higher linkage to care [20].
Conclusion
In an Asian population with a high HBV prevalence, we 
found that screening based on POC tests results in lower 
costs per person screened (76.5%), and a 2.5 times higher 
linkage to care.
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